echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > KRAS inhibitor Qinhao Pharmaceutical submits its first IND in China

    KRAS inhibitor Qinhao Pharmaceutical submits its first IND in China

    • Last Update: 2021-04-14
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Source: Guanlan Pharmaceutical

    Today (April 2), Gen House announced that the Center for Drug Evaluation (CDE) of the China National Medical Products Administration has recently accepted the clinical trial application for its Class 1 new drug GH35.


    Screenshot source: CDE official website

    GH35 is a KRAS G12C inhibitor developed by Qinhao Pharmaceutical.


    Studies have shown that KRAS gene mutations exist in a variety of tumors, among which G12C mutations are mainly found in lung cancer, colorectal cancer and pancreatic cancer.


    Note: The original text has been deleted

    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.